Haematology patients infected with SARS-CoV-2, pretreated with eculizumab or siltuximab, develop oligosymptomatic disease | European Journal of Hospital Pharmacy

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PostScript

Letter

Haematology patients infected with SARS-CoV-2, pretreated with eculizumab or siltuximab, develop oligosymptomatic disease

Online download statistics by month:

Online download statistics by month: February 2021 to March 2024

	Abstract	Full	Pdf
Feb 2021	718	713	65
Mar 2021	392	389	14
Apr 2021	142	142	20
May 2021	98	98	12
Jun 2021	37	37	7
Jul 2021	45	41	20
Aug 2021	43	46	7
Sep 2021	27	28	10
Oct 2021	158	158	22
Nov 2021	94	91	30
Dec 2021	87	87	11
Jan 2022	102	100	14
Feb 2022	65	66	7
Mar 2022	78	78	7
Apr 2022	98	98	13
May 2022	101	100	20
Jun 2022	80	79	6
Jul 2022	92	92	13
Aug 2022	114	113	17
Sep 2022	97	97	11
Oct 2022	334	77	14
Nov 2022	694	6	7
Dec 2022	314	2	6
Jan 2023	140	2	9
Feb 2023	92	1	1
Mar 2023	58	0	0
Apr 2023	40	0	1
May 2023	48	0	0
Jun 2023	50	0	0
Jul 2023	41	0	0
Aug 2023	29	0	2
Sep 2023	23	0	0
Oct 2023	40	0	0
Nov 2023	59	1	2
Dec 2023	46	2	1
Jan 2024	27	0	1
Feb 2024	47	0	2
Mar 2024	58	2	0
Total	4808	2746	372